Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akorn, Inc.    AKRX

AKORN, INC.

(AKRX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Fresenius makes solid start to year after turbulent 2018

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2019 | 12:56pm EDT
FILE PHOTO: Samples of products of Fresenius and Fresenius Medical Care are on display during the company's annual news conference at their head quarters in Bad Homburg

BERLIN (Reuters) - Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation.

The German group has flagged 2019 as an investment year as it steps up a drive to improve German hospitals that have suffered from declining admissions and high staff turnover. It also wants to scale up its home dialysis business.

Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. Operating profit rose 2 percent to 1.11 billion euros.

"All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.

Fresenius had a turbulent 2018 as it grappled with operating problems at two of its three major businesses and was tied up with a court battle over its aborted takeover of generic drugmaker Akorn, which it won.

Bankhaus Lampe analysts were encouraged the company had managed to stop the margin erosion at its Helios Germany hospitals business, even though sales fell 6 percent and operating profit declined 16 percent, hurt by a nursing shortage and a less pronounced flu season.

"We see our thesis supported that none of the businesses are facing material structural challenges," wrote analyst Volker Braun, who rates the stock 'buy'.

But Jefferies analyst James Vane-Tempest said it was too early to call a stabilisation trend at Helios given the company faces challenges from reforms to the German hospital payments system that kick in next year.

Shares in Fresenius, which have surged 19 percent so far this year, outperforming a 9.6 percent increase in the European health sector index, pared early gains to trade 0.1 percent lower at 0942 GMT.

At Fresenius Medical Care, which has faced a slowdown in North America, its most important market, adjusted sales rose 6 percent to 4.13 billion euros, helped by agreements that materialised earlier than planned.

Operating profit increased by 4 percent in constant currencies to 551 million euros.

Adjusted quarterly sales at Kabi rose 4 percent, while revenue at its smallest division Vamed, which manages projects for hospitals and provides post-acute care in central Europe, jumped 33 percent.

Despite expected earnings dilution from its $2 billion acquisition of home dialysis maker NxStage, Fresenius confirmed its guidance for currency-adjusted sales growth of 3-6 percent this year compared with 6 percent last year, while profit is expected to stay around the same level as 2018.

($1 = 0.8923 euros)

(Reporting by Caroline Copley; Editing by Jason Neely and Mark Potter)

By Caroline Copley

Stocks mentioned in the article
ChangeLast1st jan.
AKORN, INC. -1.69% 4.65 Delayed Quote.39.53%
FRESENIUS 0.53% 47.61 Delayed Quote.12.34%
FRESENIUS MEDICAL CARE 0.00% 68.26 Delayed Quote.20.52%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AKORN, INC.
06/25AKORN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
06/25Akorn Receives FDA Warning Letter
GL
05/30AKORN : Report of unscheduled material events or corporate event
PU
05/30AKORN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
05/30Akorn to Present at the Jefferies 2019 Global Healthcare Conference
GL
05/21AKORN : Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
AQ
05/21AKORN : to Present at the RBC Capital Markets Healthcare Conference
AQ
05/20AKORN : Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
AQ
05/20AKORN : Report of unscheduled material events or corporate event
PU
05/20AKORN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
More news
Financials ($)
Sales 2019 692 M
EBIT 2019 38,3 M
Net income 2019 -138 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 0,86x
EV / Sales 2020 -0,07x
Capitalization 595 M
Chart AKORN, INC.
Duration : Period :
Akorn, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKORN, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 6,60 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Douglas S. Boothe President, Chief Executive Officer & Director
Alan D. Weinstein Chairman
Christopher C. Young Executive Vice President-Global Operations
Duane A. Portwood CFO & Executive Vice President
Mark M. Silverberg Executive VP-Operations & Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
AKORN, INC.39.53%510
JOHNSON & JOHNSON10.10%348 981
PFIZER0.05%233 072
ROCHE HOLDING LTD.13.50%227 848
NOVARTIS21.44%220 893
MERCK AND COMPANY11.91%206 641